Voyager Therapeutics is a clinical-stage biotechnology enterprise dedicated to developing life-changing genetic medicines and neurogenetic treatments for severe central nervous system disorders. The company leverages its proprietary TRACER capsid discovery platform, which utilizes machine learning and directed evolution to engineer novel adeno-associated virus capsids capable of penetrating the blood-brain barrier efficiently. By combining these advanced vector generation technologies with targeted gene therapy pipelines, the enterprise aims to treat challenging conditions like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.